Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Colorectal Cancer Metastatic

Phase 3

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: AFLIBERCEPT
Drug: Irinotecan
Drug: Fluorouracil
Drug: Leucovorin

First Posted Date: 2012-08-22

Last Posted Date: 2016-11-28

Lead Sponsor: Sanofi

Target Recruit Count: 175

Registration Number: NCT01670721

Locations: 🇫🇷
Administrative office, Paris, France

Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Acinar Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas

Interventions: Drug: metformin hydrochloride
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis

First Posted Date: 2012-08-16

Last Posted Date: 2021-08-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT01666730

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Phase 2

Completed

Conditions: Pancreatic Cancer
Biliary Cancer

Interventions: Drug: Gemcitabine
Drug: 5-FU
Drug: Cisplatin

First Posted Date: 2012-08-09

Last Posted Date: 2016-10-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 39

Registration Number: NCT01661114

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Pancreatic Acinar Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

Interventions: Drug: Akt Inhibitor MK2206
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Selumetinib

First Posted Date: 2012-08-07

Last Posted Date: 2016-03-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 137

Registration Number: NCT01658943

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente-Riverside, Riverside, California, United States
🇺🇸
Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States

and more 530 locations

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-fluorouracil
Drug: Cetuximab
Drug: Irinotecan
Drug: MEHD7945A
Drug: Leucovorin

First Posted Date: 2012-07-30

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 135

Registration Number: NCT01652482

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Phase 2

Conditions: Signet Ring Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Mucinous Adenocarcinoma of the Colon
Stage IV Rectal Cancer
Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon

Interventions: Biological: aflibercept
Drug: oxaliplatin
Drug: leucovorin
Drug: fluorouracil
Other: Correlative Studies
Procedure: DCE MRI
Radiation: f18FDG-PET
Procedure: PET (positron emission tomography)

First Posted Date: 2012-07-27

Last Posted Date: 2019-03-26

Lead Sponsor: John Hays

Target Recruit Count: 56

Registration Number: NCT01652196

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

and more 3 locations

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Biological: Bevacizumab
Drug: Oxaliplatin
Drug: Irinotecan
Drug: 5-Fluorouracil

First Posted Date: 2012-07-26

Last Posted Date: 2019-10-07

Lead Sponsor: University College, London

Target Recruit Count: 20

Registration Number: NCT01650428

Locations: 🇬🇧
Wexham Park Hospital, Slough, United Kingdom
🇬🇧
UCLH, London, United Kingdom
🇬🇧
Blackpool Victoria Hospital, Blackpool, United Kingdom

and more 8 locations

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Phase 1

Completed

Conditions: Adenocarcinoma of the Gallbladder
Adenocarcinoma of Unknown Primary
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Acinar Cell Adenocarcinoma of the Pancreas
Cholangiocarcinoma of the Gallbladder
Diffuse Adenocarcinoma of the Stomach
Duct Cell Adenocarcinoma of the Pancreas
Intestinal Adenocarcinoma of the Stomach

Interventions: Drug: oxaliplatin
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis

First Posted Date: 2012-07-18

Last Posted Date: 2020-05-08

Lead Sponsor: University of Chicago

Target Recruit Count: 79

Registration Number: NCT01643499

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Phase 2

Completed

Conditions: Solid Tumors

Interventions: Biological: Ramucirumab (IMC-1121B)
Drug: Irinotecan
Drug: Folinic acid
Drug: 5-Fluorouracil

First Posted Date: 2012-07-06

Last Posted Date: 2019-02-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT01634555

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pittsburgh, Pennsylvania, United States

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Atezolizumab
Drug: 5-FU
Drug: Bevacizumab
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2012-07-06

Last Posted Date: 2020-10-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 240

Registration Number: NCT01633970

Locations: 🇺🇸
Uni of Chicago, Chicago, Illinois, United States
🇺🇸
Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville, North Carolina, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy